Lipum Q1: Initiating preparations for phase II - Redeye

Redeye provides a research update following the Q1 report published by Lipum earlier today. While the report did not include any major surprises, we focus on the recent events surrounding the company. With a bolstered cash position following the recent rights issue, Lipum is set to initiate preparations for the upcoming phase II trials. We reiterate our valuation of Lipum with a base case of SEK15.

Länk till analysen i sin helhet: https://www.redeye.se/research/1012145/lipum-q1-initiating-preparations-for-phase-ii?utm_source=finwire&utm_medium=RSS